Pentoxifylline

Generic Name: Pentoxifylline

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈N_₄O_₃

CAS Number: 6493-05-6

Unique Ingredient Identifier: SD6QCT3TSU

Background: Pentoxifylline (PTX) is a synthetic dimethylxanthine derivative that modulates the rheological properties of blood and also has both anti-oxidant and anti-inflammatory properties. Although originally developed to treat intermittent claudication, a form of exertion-induced leg pain common in patients with peripheral arterial disease, PTX has been investigated...

Indication: Pentoxifylline is indicated for the treatment of intermittent claudication in patients with chronic occlusive arterial disease. Pentoxifylline may improve limb function and reduce symptoms but cannot replace other therapies such as surgical bypass or removal of vascular obstructions.

Associated Conditions: Intermittent Claudication, Venous Leg Ulcer (VLU), Severe alcoholic liver disease

Associated Therapies: -

Clinical Trials

Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)

Phase 2

Completed

Conditions: Major Depressive Disorder
Depression
Depressive Symptoms
Cardiovascular Disease (CVD)
Coronary Artery Disease (CAD)
Heart Disease

Interventions: Other: Placebo
Drug: Pentoxifylline
Behavioral: Standard Treatment

First Posted Date: 2012-06-21

Last Posted Date: 2015-12-03

Lead Sponsor: Indiana University

Target Recruit Count: 36

Registration Number: NCT01625845

Locations: 🇺🇸
Indiana University-Purdue University Indianapolis (IUPUI), Indianapolis, Indiana, United States

Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS)

Phase 4

Conditions: Irritable Bowel Syndrome

Interventions: Drug: pentoxifylline placebo
Drug: pentoxifylline

First Posted Date: 2012-03-02

Last Posted Date: 2012-03-06

Lead Sponsor: Hospital Universitario de Canarias

Target Recruit Count: 59

Registration Number: NCT01542268

Locations: 🇪🇸
Complejo Hospitalario Universitario de Canarias, La Laguna, S/c Tenerife, Spain

Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis

Phase 2

Completed

Conditions: Brain Metastasis

Interventions: Drug: Trental
Dietary Supplement: Vitamin E

First Posted Date: 2012-01-11

Last Posted Date: 2023-09-14

Lead Sponsor: University of Cincinnati

Target Recruit Count: 31

Registration Number: NCT01508221

Locations: 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases

Phase 3

Completed

Conditions: Tropical Spastic Paraparesis
Physical Disability
Immune System Diseases
HTLV-1
Pentoxifylline

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2011-11-16

Last Posted Date: 2015-03-18

Lead Sponsor: Hospital Universitário Professor Edgard Santos

Target Recruit Count: 48

Registration Number: NCT01472263

Locations: 🇧🇷
Hospital Universitário Professor Edgard Santos, Salvador, Bahia, Brazil

Evaluating the Protective Effect of Pentoxifylline on Contrast Induced Nephropathy

Not Applicable

Conditions: Nephropathy

Interventions: Drug: Pentoxifylline

First Posted Date: 2011-11-10

Last Posted Date: 2011-11-10

Lead Sponsor: Shiraz University of Medical Sciences

Registration Number: NCT01469624

Locations: 🇮🇷
University Hospitals, Shiraz, Fars, Iran, Islamic Republic of

Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis

Phase 2

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Meglumine antimonate
Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2011-11-03

Last Posted Date: 2016-08-23

Lead Sponsor: Centro Internacional de Entrenamiento e Investigaciones Médicas

Target Recruit Count: 75

Registration Number: NCT01464242

Locations: 🇨🇴
Corporación Centro Internacional de entrenamiento e Investigaciónes Médicas, Cali, Valle, Colombia

Short-term Survival in Patients With Severe Alcoholic Hepatitis Treated With Steroid Versus Pentoxifylline

Phase 3

Conditions: Alcoholic Hepatitis

Interventions: Drug: Prednisolone
Drug: pentoxifylline

First Posted Date: 2011-10-19

Last Posted Date: 2011-10-19

Lead Sponsor: Inje University

Target Recruit Count: 126

Registration Number: NCT01455337

Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2011-06-27

Last Posted Date: 2017-06-16

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 174

Registration Number: NCT01382303

Locations: 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of

Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis

Phase 2

Completed

Conditions: Cutaneous Leishmaniasis

Interventions: Drug: Placebo
Drug: Pentoxifylline

First Posted Date: 2011-06-27

Last Posted Date: 2017-01-26

Lead Sponsor: Paulo Roberto Lima Machado

Target Recruit Count: 164

Registration Number: NCT01381055

Locations: 🇧🇷
Posto de Saúde de Corte de Pedra, Corte de Pedra, Tancredo Neves/Bahia, Brazil

Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)

Phase 4

Conditions: Chronic Renal Failure

Interventions: Drug: ARB
Drug: Pentoxifylline
Drug: Placebo (for Pentoxifylline)

First Posted Date: 2011-06-21

Last Posted Date: 2016-10-14

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 350

Registration Number: NCT01377285

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy